Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $590.04M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 1.13M
Average 1.07M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Abivax S.A. NASDAQ:ABVX | $7.67B | $87.58 | Not rated | -18.1 | -34.38% |
Arcus Biosciences, Inc. NYSE:RCUS | $2.51B | $17.43 | Not rated | -8.2 | -25.67% |
Celldex Therapeutics, Inc. NASDAQ:CLDX | $2.26B | $28.83 | Not rated | -7.8 | +11.53% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | -11.29% |
CytomX Therapeutics, Inc. NASDAQ:CTMX | $444.73M | $2.04 | Not rated | -8.8 | -45.62% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +44.53% |
Immunic, Inc. NASDAQ:IMUX | $102.61M | $7.52 | Not rated | -4.1 | +7.41% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $56.49M | $0.73 | Not rated | -1.8 | -54.46% |
NovaBridge Biosciences NASDAQ:NBP | $42.59M | $0.85 | Not rated | -25.5 | -79.00% |
Immutep Limited NASDAQ:IMMP | $25.64M | $3.48 | Not rated | -0.9 | -77.91% |
Continue the stock analysis
Jump to another research area for this company.